Works matching IS 03407004 AND DT 2000 AND VI 49 AND IP 1
Results: 6
Phase I trial of interleukin-2 and high-dose arginine butyrate in metastatic colorectal cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2000, v. 49, n. 1, p. 56, doi. 10.1007/s002620050026
- By:
- Publication type:
- Article
Immune gene therapy of experimental mouse brain tumor with adenovirus-mediated gene transfer of murine interleukin-4.
- Published in:
- Cancer Immunology, Immunotherapy, 2000, v. 49, n. 1, p. 23, doi. 10.1007/s002620050023
- By:
- Publication type:
- Article
Tumor-derived Fas ligand induces toxicity in lymphoid organs and plays an important role in successful chemotherapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2000, v. 49, n. 1, p. 46, doi. 10.1007/s002620050025
- By:
- Publication type:
- Article
Immunotherapy with vaccines combining MHC class II/CD80<sup>+</sup> tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon γ.
- Published in:
- Cancer Immunology, Immunotherapy, 2000, v. 49, n. 1, p. 34, doi. 10.1007/s002620050024
- By:
- Publication type:
- Article
Initial steps in lymph node metastasis formation in an experimental system: possible involvement of recognition by macrophage C-type lectins.
- Published in:
- Cancer Immunology, Immunotherapy, 2000, v. 49, n. 1, p. 1, doi. 10.1007/s002620050021
- By:
- Publication type:
- Article
B7-2 expression on tumor cells is important for the acquisition of cytotoxic T lymphocyte activity by spleen cells from low-dose-melphalan-treated MOPC-315 tumor bearers via a mechanism that requires either B7-1 or B7-2 expression on host antigen-presenting cells
- Published in:
- Cancer Immunology, Immunotherapy, 2000, v. 49, n. 1, p. 10, doi. 10.1007/s002620050022
- By:
- Publication type:
- Article